Treatment Options for Relapsed and Refractory Multiple Myeloma
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Treatment options for patients with relapsed myeloma have benefited from the development of new targeted agents. The use of bortezomib, thalidomide, and lenalidomide have dramatically changed outcomes for patients with relapsed myeloma. New agents are also in development, on the basis of preclinical rationale, as well as combinations of conventional and novel agents. Together each of these treatment approaches are being tested in phase I, II, and III clinical trials, with the goal of prolonged duration of remission and, ultimately, improved overall survival. Clin Cancer Res; 17(6); 1264–77. ©2011 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632 · cited 1×
“inhibitor with potent antimyeloma activity as a single agent (6, 62, 63).”
BackgroundSelf-citationInternational uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632 · cited 2×
“5 mg/dL is used to define disease progression.(1) ‘Relapsed and refractory’ myeloma is”
BackgroundMethodSelf-citationAntitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575 · cited 1×
“With addition of DEX (TD) the overall responses rates (ORR) were augmented to 55% compared to ORR of 24% with THAL alone.(3,4) The current role of THAL in the management of RRMM is probably restricted, largely due to the preceding use of next generation IMiDs”
MethodLenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450
Chauhan, D., Catley, L., Li, G., Podar, K., Hideshima, T., Velankar, M., Mitsiades, C., Mitsiades, N., Yasui, H., Letai, A., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.10.013 · Cited by 694 · cited 2×
“Another second-generation proteasome inhibitor in earlier clinical development is NPI-0052 (133), which is also irreversible and with a more broad-ranging inhibition of all 3 enzymatic sites within the proteasome, as opposed to the single site seen with bortezomib and carfilzomib.”
BackgroundSelf-citationRichardson, P. G., Blood, E., Mitsiades, C. S., Jagannath, S., Zeldenrust, S. R., Alsina, M., Schlossman, R. L., Rajkumar, S. V., Desikan, K. R., Hideshima, T., et al. (2006) · Blood · doi:10.1182/blood-2006-04-015909 · Cited by 523
Self-citationRichardson, P. G., Weller, E., Jagannath, S., Avigan, D. E., Alsina, M., Schlossman, R. L., Mazumder, A., Munshi, N. C., Ghobrial, I. M., Doss, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.2679 · Cited by 162 · cited 1×
“excellent tolerability in this context (95).”
Self-citationPineda-Roman, M., Zangari, M., van Rhee, F., Anaissie, E., Szymonifka, J., Hoering, A., Petty, N., Crowley, J., Shaughnessy, J., Epstein, J., et al. (2008) · Leukemia · doi:10.1038/leu.2008.99 · Cited by 139
Cited by
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Palumbo, A., Chanan-Khan, A., Weisel, K., Nooka, A. K., Masszi, T., Beksac, M., Spicka, I., Hungria, V., Munder, M., Mateos, M. V., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606038 · Cited by 1,522
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Moreau, P., Masszi, T., Grzasko, N., Bahlis, N. J., Hansson, M., Pour, L., Sandhu, I., Ganly, P., Baker, B. W., Jackson, S. R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516282 · Cited by 1,060
“Insomnia 73 (20) 7 (2) 0 98 (27) 11 (3) 0”
Self-citationB-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma
Carpenter, R. O., Evbuomwan, M. O., Pittaluga, S., Rose, J. J., Raffeld, M., Yang, S., Gress, R. E., Hakim, F. T., & Kochenderfer, J. N. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2422 · Cited by 653
Proteasome inhibitors in multiple myeloma: 10 years later
Moreau, P., Richardson, P. G., Cavo, M., Orlowski, R. Z., San Miguel, J. F., Palumbo, A., & Harousseau, J.-L. (2012) · Blood · doi:10.1182/blood-2012-04-403733 · Cited by 490
Self-citationRichardson, P. G., Siegel, D. S., Vij, R., Hofmeister, C. C., Baz, R., Jagannath, S., Chen, C., Lonial, S., Jakubowiak, A., Bahlis, N., et al. (2014) · Blood · doi:10.1182/blood-2013-11-538835 · Cited by 381
“Median age, y (range) 64 (34-88) 61 (37-88) 63 (34-88)”
Self-citation
Metadata
- Authors
- Lonial, S., Mitsiades, C. S., & Richardson, P. G.
- Venue
- Clinical Cancer Research
- Published
- 2011-03-15
- Volume
- 17
- Issue
- 6
- Pages
- 1264-1277
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2169774815
- Cited by
- 127
- References
- 8
- FWCI
- 11.88
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment Options for Relapsed and Refractory Multiple Myeloma. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-10-1805
- The paper
- Lonial, S., Mitsiades, C. S., & Richardson, P. G. (2011). Treatment Options for Relapsed and Refractory Multiple Myeloma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-10-1805
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.